- Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
- Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
- Orexo publishes the Annual and Sustainability Report for 2023
- Correction: Notice of Annual General Meeting of Orexo
- Notice of Annual General Meeting of Orexo
- Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds
- Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds
- Orexo strengthens its sustainability work by establishing a social financing framework
- Orexo and Sobi agree to advance feasibility study with AmorphOX
- Orexo Interim Report Q4 2023, incl. Full Year Report
More ▼
Key statistics
As of last trade Orexo AB (ORX:STO) traded at 17.20, -14.43% below its 52-week high of 20.10, set on Jul 03, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.54 |
---|---|
High | 17.54 |
Low | 16.42 |
Bid | 17.12 |
Offer | 17.20 |
Previous close | 17.50 |
Average volume | 9.12k |
---|---|
Shares outstanding | 34.71m |
Free float | 27.39m |
P/E (TTM) | -- |
Market cap | 607.44m SEK |
EPS (TTM) | -3.73 SEK |
Data delayed at least 15 minutes, as of Apr 18 2024 12:36 BST.
More ▼